Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 3, 2012, Pages 204-209

  Wu, Hongju ^a   Xin, Yan ^a   Xiao, Yuping ^a   Zhao, Jing ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

angiogenesis; docetaxel; EGCG; gastric cancer; metronomic chemotherapy

Indexed keywords

DOCETAXEL; EPIGALLOCATECHIN GALLATE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DENSITY; DOSE RESPONSE; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW DOSE METRONOMIC CHEMOTHERAPY; MICROVASCULATURE; MICROVESSEL DENSITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CATECHIN; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; STOMACH NEOPLASMS; TAXOIDS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859562692     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1103     Document Type: Article

References (34)

1. Albert A. New drugs in the treatment of gastric tumors. Clin Transl Oncol 2008;10:256.
2. Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006;17:961.
3. Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy is changing the paradigm that more is better. Curr Oncol 2009;16:7.
4. Tetzlaff ED, Cheng JD, Ajani JA. Review of docetaxel in the treatment of gastric cancer. Ther Clin Risk Manag 2008; 4:999.
5. Benelli R, Monteghirfo S, Balbi C, et al. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int J Cancer 2009;124:2989.
6. Bergers G, Hanahan D. Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harb Symp Quant Biol 2002;67:293.
7. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia. J Clin Oncol 2008;26:76.
8. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15.
9. Khan N, Afaq F, Saleem M, et al. Targeting multiple signaling pathways by green tea polyphenol (-) -epigallocatechin- 3-gallate. Cancer Res 2006;66:2500.
10. Neuhaus T, Pabst S, Stier S, et al. Inhibition of the vascularendothelial growth factor-induced intracellular signaling and mitogenesis of human endothelial cells by epigallocatechin- 3 gallate. Eur J Pharmacol 2004;483:223.
11. Fassina G, Vene R, Morini M, et al. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res 2004;10:4865.
12. Hongju Wu, Yan Xin, Jing Zhao, et al. Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model. Cancer Chemother Pharmacol 2011;68:879.
13. Dykes DJ, Bissery MC, Harrison SD, et al. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest New Drugs 1995;13:1.
14. Kamat AA, Kim TJ, Landen CN, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007;67:281.
15. Jung YD, Kim MS, Shin BA, et al. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 2001;84:844.
16. Zhu BH, Zhan WH, Li ZR, et al. (-)-Epigallocatechin-3- gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J Gastroenterol 2007; 13:1162.
17. Bocci G, Falcone A, Fioravanti A, et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 2008;98:1619.
18. Liu TG, Huang Y, Cui D, et al. Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice statistical analysis. BMC Cancer 2009;9:250.
19. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423.
20. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938.
21. Zhang M, Tao W, Pan S, et al. Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts. Anticancer Drugs 2009;20:355.
22. Zhang Q, Kang X, Zhao W. Antiangiogenic effect of lowdose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma. Biochem Biophys Res Commun 2006;342:824.
23. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents. Bioessays 1991;13:31.
24. Castilla MA, Caramelo C, Gazapo RM, et al. Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents. Life Sci 2000;67:1003.
25. Folkman J. What is the evidence that tumors are angiogenesis dependent. J Natl Cancer Inst 1990;82:4.
26. Bando H. Vascular endothelial growth factor and bevacitumab in breast cancer. Breast Cancer 2007;14:163.
27. Hayes DF, Miller K, Sledge G. Angiogenesis as targeted breast cancer therapy. Breast 2007;16(supp2):S17.
28. Magnon C, Galaup A, Rouffiac V, et al. Dynamic assessment of antiangiogenic therapy by monitoring both tumoral vascularization and tissue degeneration. Gene Ther 2007;14:108.
29. Maria RR, Francesca C, Francesca G. Microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int J Surg Pathol 2005;13:135.
30. Ji Y, Hayashi K, Amoh Y, et al. The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer. Anticancer Res 2007;27:713.
31. Mei Y, Qian F, Wei D, et al. Reversal of cancer multidrug resistance by green tea polyphenols. J Pharm Pharmacol 2004;56:1307.
32. Hong J, Lambert JD, Lee SH, et al. Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun 2003;310:222.
33. Hong J, Lu H, Meng X, et al. Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin- 3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res 2002;62:7241.
34. Lang M, Henson R, Braconi C, et al. Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver Int 2009;29:670.